Indivior raises 2026 guidance on SUBLOCADE strength, advances merger with Supernus
Aug 3, 2026, 6:34 AM EDT1 sourcesAI-analyzed
Why it may matterVerify against the original reporting
Key catalysts include raised 2026 guidance and a pending all-stock merger with Supernus, likely driving near-term stock re-rating; execution and integration risk remain, but constructive guidance and scale benefits support upside.
AI summary
What happened, with direct paths to the underlying reporting
Indivior posted strong Q2 2026 results with total net revenue of $343 million, up 14% YoY, and SUBLOCADE net revenue of $253 million, up 21% YoY. The company raised its 2026 guidance and disclosed an all-stock merger with Supernus to close in Q4 2026, signaling substantial scale and CNS-focused growth potential alongside ongoing SUBLOCADE momentum.
Q2 2026 total net revenue: $343m, +14% YoY; SUBLOCADE net revenue: $253m, +21% YoY.
Q2 2026 US SUBLOCADE net revenue $238m, +22% YoY; new starts 32,816, 18% dispense growth.
2026 guidance raised: net revenue $1,295–$1,365m; SUBLOCADE $1,010–$1,050m; EBITDA $700–$740m.
Indivior to merge with Supernus in an all-stock deal; closing expected in Q4 2026.
Q2 2026 share repurchases: 4.66m shares for $175m; YTD: ~8.64m shares for $300m.
How to read this signal
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.
Related signals
More source-backed signals connected by company or event
The article highlights oversold healthcare stocks with RSI near 30, suggesting possible near-term mean reversion. Legend Biotech’s CEO Ying Huang resigned on July 27, contributing…
Indivior posted strong Q2 2026 results with record SUBLOCADE revenue and raised full-year guidance, highlighting accelerating growth. Management also announced a definitive all-st…